» Articles » PMID: 14699145

Phospholipids Can Switch the GTPase Substrate Preference of a GTPase-activating Protein

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 Dec 31
PMID 14699145
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The major cellular inhibitors of the small GTPases of the Ras superfamily are the GTPase-activating proteins (GAPs), which stimulate the intrinsic GTP hydrolyzing activity of GTPases, thereby inactivating them. The catalytic activity of several GAPs is reportedly inhibited or stimulated by various phospholipids and fatty acids in vitro, indicating a likely physiological role for lipids in regulating small GTPases. We find that the p190 RhoGAP, a potent GAP for the Rho and Rac GTPases, is similarly sensitive to phospholipids. Interestingly, however, several of the tested phospholipids were found to effectively inhibit the RhoGAP activity of p190 but stimulate its RacGAP activity. Thus, phospholipids have the ability to "switch" the GTPase substrate preference of a GAP, thereby providing a novel regulatory mechanism for the small GTPases.

Citing Articles

Anillin tunes contractility and regulates barrier function during Rho flare-mediated tight junction remodeling.

Craig Z, Arnold T, Walworth K, Walkon A, Miller A bioRxiv. 2024; .

PMID: 39605712 PMC: 11601591. DOI: 10.1101/2024.11.20.624537.


p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP.

OuYang H, Wu S, Li W, Grey M, Wu W, Hansen S Cell Rep. 2023; 42(12):113486.

PMID: 37995182 PMC: 10809936. DOI: 10.1016/j.celrep.2023.113486.


The scaffold RhoGAP protein ARHGAP8/BPGAP1 synchronizes Rac and Rho signaling to facilitate cell migration.

Wong D, Pan C, Er S, Thivakar T, Rachel T, Seah S Mol Biol Cell. 2023; 34(3):ar13.

PMID: 36598812 PMC: 10011724. DOI: 10.1091/mbc.E21-03-0099.


Fixing the GAP: The role of RhoGAPs in cancer.

Kreider-Letterman G, Carr N, Garcia-Mata R Eur J Cell Biol. 2022; 101(2):151209.

PMID: 35180567 PMC: 9081277. DOI: 10.1016/j.ejcb.2022.151209.


The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.

Sanchez-Solana B, Wang D, Qian X, Velayoudame P, Simanshu D, Acharya J Mol Cancer. 2021; 20(1):141.

PMID: 34727930 PMC: 8561924. DOI: 10.1186/s12943-021-01439-y.